A series of cardiometabolic-related news items has been observed from Novo Nordisk, Novartis, Aspen Pharmacare, Medtrum, and Hilo. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from AstraZeneca/CSPC Pharmaceutical, Amgen, Ascletis Pharma, Regeneron Pharmaceuticals, Trinity Biotech, MHRA, Adocia, and ViCentra. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from The Obesity Action Coalition, Hengrui, Terrestrial Bio, Tandem Diabetes Care, and Tufts Health Direct. Below, FENIX provides highlights and insights into the respective news items.
A series of cardiometabolic-related news items has been observed from Viking Therapeutics, Lilly/Oura, Modular Medical, Wave Life Sciences, Novo Nordisk, and Ionis Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.
On the first day of the ADA 2026 conference, six cardiometabolic-related news items have been observed from Tandem, Veru, Gan & Lee, Cigna, Bayer, and Structure Therapeutics. Below, FENIX provides context and analysis for the announcements.
A series of cardiometabolic-related news items has been observed from FDA, AstraZeneca, Dexcom, and EMA. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Madrigal Pharmaceuticals hosted its Q1 ’26 earnings call (view press release; view slides) and Insulet hosted its Q1 ’26 earnings call (view press release; view slides). Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Lilly aired a new Foundayo DTC ad on social media platforms (view Reddit post); Roche’s CT-388 has been given the INN of enicepatide, which is reflected in two Ph2 studies (view CT.gov record; view CT.gov record); and the CHMP agenda for this month’s meeting (April 20-23) has been released (view here). Below, FENIX provides highlights and insights on the respective news items.
A series of cardiometabolic-related news items has been observed by Lilly, FDA, Novo Nordisk, 23andMe, and Noom. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Whoop, Currax Pharmaceuticals, Novo Nordisk, and Ambrosia Biosciences. Below, FENIX provides highlights and insights for the respective news items.